Ken Aho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ken Aho has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Brandon Roan
Division of Health Sciences, Idaho State University, 921 S 8th Avenue, Mail Stop 8288, Pocatello, ID 83209, USA
1 shared publication - Korawin Triyasakorn
Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Idaho State University, 921 S 8th Avenue, Mail Stop 8288, Pocatello, ID 83209, USA
1 shared publication - Minsyusheen Conlin
Department of Biological Sciences, Idaho State University, 921 S 8th Avenue, Mail Stop 8288, Pocatello, ID 83209, USA
1 shared publication - Prabha S. Awale
Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Idaho State University, 921 S 8th Avenue, Mail Stop 8288, Pocatello, ID 83209, USA
1 shared publication - Ubah Dominic Babah Ubah
Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Idaho State University, 921 S 8th Avenue, Mail Stop 8288, Pocatello, ID 83209, USA
1 shared publication
Latest Publications
- Open Access
The Antiepileptic Drug and Toxic Teratogen Valproic Acid Alters Microglia in an Environmental Mouse Model of Autism
Autism spectrum disorder (ASD), a neurodevelopmental condition affecting approximately 1 in 44 children in North America, is thought to be a connectivity disorder. Valproic acid (VPA) is a multi-target drug widely used to treat epilepsy. It is also a toxic teratogen as well as a histone deacetylase inhibitor, and fetal exposure to VPA increases the risk of ASD. While the VPA model has been well-characterized for behavioral and neuronal deficits including hyperconnectivity, microglia, the principal immune cells of CNS that regulate dendrite and synapse formation during early brain development, have not been well-characterized and may provide potential hints regarding the etiology of this disorder. Therefore, in this study, we determined the effect of prenatal exposure to VPA on microglial numbers during early postnatal brain development. We found that prenatal exposure to VPA causes a significant reduction in the number of microglia in the primary motor cortex (PMC) during early postnatal brain development, particularly at postnatal day 6 (P6) and postnatal day 10 (P10) in male mice. The early microglial reduction in the VPA model coincides with active cortical synaptogenesis and is significant because it may potentially play a role in mediating impaired connectivity in ASD.
Open AccessThe Antiepileptic Drug and Toxic Teratogen Valproic Acid Alters Microglia in an Environmental Mouse Model of Autism
Autism spectrum disorder (ASD), a neurodevelopmental condition affecting approximately 1 in 44 children in North America, is thought to be a connectivity disorder. Valproic acid (VPA) is a multi-target drug widely used to treat epilepsy. It is also a toxic teratogen as well as a histone deacetylase inhibitor, and fetal exposure to VPA increases the risk of ASD. While the VPA model has been well-characterized for behavioral and neuronal deficits including hyperconnectivity, microglia, the principal immune cells of CNS that regulate dendrite and synapse formation during early brain development, have not been well-characterized and may provide potential hints regarding the etiology of this disorder. Therefore, in this study, we determined the effect of prenatal exposure to VPA on microglial numbers during early postnatal brain development. We found that prenatal exposure to VPA causes a significant reduction in the number of microglia in the primary motor cortex (PMC) during early postnatal brain development, particularly at postnatal day 6 (P6) and postnatal day 10 (P10) in male mice. The early microglial reduction in the VPA model coincides with active cortical synaptogenesis and is significant because it may potentially play a role in mediating impaired connectivity in ASD.